<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We carried out a secondary analysis in high-risk patients with a previous <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI) and <z:mp ids='MP_0002055'>diabetes</z:mp> in the Alpha Omega Trial </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that in these patients an increased intake of the n-3 fatty acids eicosapentaenoic acid (<z:chebi fb="113" ids="28364">EPA</z:chebi>), <z:chebi fb="0" ids="36005">docosahexaenoic acid</z:chebi> (DHA), and Î±-<z:chebi fb="0" ids="25048,27432">linolenic acid</z:chebi> (ALA) will reduce the incidence of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and fatal MI </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A subgroup of 1,014 post-MI patients with <z:mp ids='MP_0002055'>diabetes</z:mp> aged 60-80 years was randomly allocated to receive one of four trial margarines, three with an additional amount of n-3 fatty acids and one placebo for 40 months </plain></SENT>
<SENT sid="3" pm="."><plain>The end points were <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>-related events and fatal MI </plain></SENT>
<SENT sid="4" pm="."><plain>The data were analyzed according to the intention-to-treat principle, using multivariable Cox proportional hazards models </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The patients consumed on average 18.6 g of margarine per day, which resulted in an additional intake of 223 mg <z:chebi fb="113" ids="28364">EPA</z:chebi> plus 149 mg DHA and/or 1.9 g ALA in the active treatment groups </plain></SENT>
<SENT sid="6" pm="."><plain>During follow-up, 29 patients developed a <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>-related events and 27 had a fatal MI </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with placebo patients, the <z:chebi fb="113" ids="28364">EPA</z:chebi>-DHA plus ALA group experienced less <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>-related events (hazard ratio 0.16; 95% CI 0.04-0.69) </plain></SENT>
<SENT sid="8" pm="."><plain>These n-3 fatty acids also reduced the combined end-point <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>-related events and fatal MI (0.28; 0.11-0.71) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Our results suggest that low-dose supplementation of n-3 fatty acids exerts a protective effect against <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>-related events in <z:e sem="disease" ids="C0856742" disease_type="Disease or Syndrome" abbrv="">post-MI</z:e> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>